Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
about
Targeting inflammation in diabetes: Newer therapeutic optionsInflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targetsAdditive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARsPioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic ratsOpposite action of peroxisome proliferator-activated receptor-gamma in regulating renal inflammation: functional switch by its ligandProstaglandin signaling regulates nephron segment patterning of renal progenitors during zebrafish kidney developmentPPAR-gamma agonists inhibit TGF-beta1-induced chemokine expression in human tubular epithelial cells.GW501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice.PPAR-alpha and PPAR-beta expression changes in the hippocampus of rats undergoing global cerebral ischemia/reperfusion due to PPAR-gamma statusQuercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation.Comparative analysis of the relationship between trichloroethylene metabolism and tissue-specific toxicity among inbred mouse strains: kidney effects.Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.Nuclear receptors in renal diseaseComparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: protection from injury and molecular effects.High-calorie diet partially ameliorates dysregulation of intrarenal lipid metabolism in remnant kidney.Therapeutic approach to FSGS in children.hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.Mechanisms of progression of chronic kidney diseaseRenal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases.Attrition of Hepatic Damage Inflicted by Angiotensin II with α-Tocopherol and β-Carotene in Experimental Apolipoprotein E Knock-out MicePeroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblastsThiazolidinediones: effects on insulin resistance and the cardiovascular system.Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertensionPioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome.Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseasesPPARs and the kidney in metabolic syndrome.Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?Correlation between PPAR Gene Polymorphisms and Primary Nephrotic Syndrome in ChildrenRenal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney.The pathophysiology of hypertension in systemic lupus erythematosus.Peroxisome proliferator-activated receptors in diabetic nephropathy.Transcription factors Krüppel-like factor 6 and peroxisome proliferator-activated receptor-{gamma} mediate high glucose-induced thioredoxin-interacting protein.Effects of taurine and housing density on renal function in laying hensNew Insights into the PPAR γ Agonists for the Treatment of Diabetic Nephropathy.The effects of dual PPARα/γ agonism compared with ACE inhibition in the BTBRob/ob mouse model of diabetes and diabetic nephropathy.Peroxisome proliferator activating receptor-γ and the podocyte.Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved.Oxidative stress-induced alterations in PPAR-γ and associated mitochondrial destabilization contribute to kidney cell apoptosis.
P2860
Q26852726-461044EC-6E8B-475D-886C-E04888B66A48Q26866480-14D062B6-4588-41A9-9D9B-A2E3139B1323Q28550672-B89591ED-B045-4850-93EB-06AFABC91345Q28580246-4E319D75-DEA9-4A16-BD79-DA32D84EA0B2Q28581020-9A4A1D43-B821-4BBD-8605-2174B2D7AB78Q28816964-46027A4A-CD87-41CE-8335-0D4DD2D16093Q33552194-5204112A-40E5-4AAB-9257-D70826058847Q34038147-F8A546AA-59B1-40B5-8F6E-551918B1DFD3Q34203838-C1E23F82-1FE0-4FF8-9446-B7CB5B457A77Q34305376-651D4A9D-7E5D-4966-B418-BBEEAFBFECA6Q34802950-9CCA0D4F-A597-4FA7-8D2B-F79D34C9230DQ34926845-C0FBBBE7-FA5A-4B80-8159-41BE2A33C6D9Q35120702-F3E0E7AE-5517-40E9-B2B5-C2124165CFE8Q35188070-047562A6-BA64-4328-8720-2286B9C70F09Q35500577-F7836073-7D02-4CE3-83FD-107CB4EEBB0FQ35614311-6BDCEDFB-3B4A-47BF-8617-267BBFCA6E3DQ35677086-5C6E5E7F-BC2A-4DAA-82A2-B45C16F4A367Q36120044-909269AC-A4AE-47C1-A897-D15B8E10E146Q36182173-BFAAE22C-9BEC-4EAA-9874-4896D173755EQ36262404-B3F8074F-3F26-4743-BCD2-DA1FB3475310Q36376266-A207B4E9-E929-452D-9547-E9802DD31E77Q36417662-7B8EB1A0-432D-4289-A31F-151DC71EE6F4Q36484662-EB0A6F29-DF0B-455E-9F40-192EEC2896E9Q36577073-D5312022-2D0B-4DFD-829F-A7F831C7B727Q36824736-0BEB5DE9-D8AE-44C7-A9DB-E29A4FC87DEAQ36864663-FF57F454-0D29-433B-BD6E-A7030C33F928Q36918509-2AF24911-25B2-407A-B488-7CC703413BEDQ37072216-AFB14E85-1CCD-4135-9646-D442A27B23A9Q37107490-1019004B-7E65-4432-AE5A-B3178D829895Q37206255-4C165213-1745-46B9-A0AF-EC672970CC0CQ37216929-077A0386-1F3B-4965-827D-A99045ADEB02Q37233020-114C212D-E3F7-4D0B-B2D4-39204553022AQ37412297-83DB1B11-EED7-40DB-AA5F-3DE3300C3086Q37413641-DB44E843-76E4-4F40-9477-457EDB6F00E6Q37518280-F05E8C5A-D877-4895-A30C-831710719103Q37590946-50955A63-7F84-449D-90A9-D249A6008EADQ37699675-94E17F4A-F92F-443C-B88A-7BC41DF50964Q38815188-7C00B0BB-A6EA-4FEA-91B3-40F233868A80Q38854862-6C21F983-FB9F-4AB5-B3BF-12CEF39A6E33Q38966233-E6A183B7-10F2-47E6-BCA8-3D5F24883EB1
P2860
Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Peroxisome proliferator-activa ...... utic targets in renal disease.
@ast
Peroxisome proliferator-activa ...... utic targets in renal disease.
@en
type
label
Peroxisome proliferator-activa ...... utic targets in renal disease.
@ast
Peroxisome proliferator-activa ...... utic targets in renal disease.
@en
prefLabel
Peroxisome proliferator-activa ...... utic targets in renal disease.
@ast
Peroxisome proliferator-activa ...... utic targets in renal disease.
@en
P1433
P1476
Peroxisome proliferator-activa ...... utic targets in renal disease.
@en
P2093
P356
10.1046/J.1523-1755.2001.00766.X
P407
P577
2001-07-01T00:00:00Z
P5875
P6179
1019971895